92% of S&P 500 market value is intangible. Yet most founders walk into valuation conversations armed with a single method — Discounted Cash Flow — built for an era when factories and inventory were the assets that mattered. Hayat Amin argues that the valuation method you choose determines whether your IP shows up in the number or vanishes from it. The 5 methods of valuation every operator needs are: Discounted Cash Flow (DCF), Comparable Company Analysis, Asset-Based Valuation, Precedent Transactions, and Relief from Royalty. Pick the wrong one and you leave 2–4x on the table.
What Are the 5 Methods of Valuation?
The 5 methods of valuation are Discounted Cash Flow (Income Approach), Comparable Company Analysis (Market Approach), Asset-Based Valuation, Precedent Transactions, and Relief from Royalty. Each method answers a different question about what a company is worth, and the right choice depends on your company’s stage, asset profile, and what you are trying to prove.
Most accountants and lawyers default to one method. Most VCs default to another. The operators who get premium outcomes use multiple methods and triangulate. That triangulation — knowing when each method applies and when it breaks — is the difference between a founder who gets fair value and one who gets gutted in negotiations.
At Beyond Elevation, every valuation engagement runs at least three of these methods side by side. Here is what each one does, where it wins, and where it fails.
Method 1: Discounted Cash Flow — When It Works and When It Breaks
DCF projects future cash flows and discounts them to present value using a risk-adjusted rate. It is the default method taught in every MBA programme and used by most corporate finance teams. For mature, cash-generating businesses with predictable revenue, DCF works.
Where it fails: pre-revenue startups, early-stage AI companies, and IP-heavy businesses where the majority of value sits in intangible assets that do not yet produce cash flow. A company with four granted patents worth $20M in licensing potential shows zero in a DCF if it has not yet signed a licensee. That is not a valuation — that is an oversight.
The deeper problem is the discount rate. For startups, discount rates of 30–60% crush the present value of any projection. The more speculative the cash flow, the less DCF captures. This is why AI company valuations almost never rely on DCF alone — the method structurally undervalues companies whose primary assets are patents, data, and know-how.
Method 2: Comparable Company Analysis — The Shortcut Every VC Uses
Comparable Company Analysis (comps) values your company based on revenue or EBITDA multiples of similar public or private companies. In 2026, AI company medians sit at 20–30x revenue for late-stage and 10–50x for early-stage, depending on defensibility and growth rate. SaaS benchmarks run 8–15x ARR.
Comps are fast, intuitive, and the language VCs already speak. An investor comparing your Series A to the last ten AI deals they saw is running comps whether they formalise it or not. The method works best when genuine comparables exist — same sector, same stage, same business model.
Where it fails: there are no comps for truly novel companies. If your IP portfolio is the primary value driver and no traded company looks like yours, comps will anchor you to a peer set that does not reflect your actual defensibility. The result is a valuation that captures your revenue but misses your moat entirely. Understanding where comps break is essential — for a deeper dive, see the Rule of 40 framework that separates SaaS benchmarking from AI-specific metrics.
Method 3: Asset-Based Valuation — Why Accountants Miss 80% of Your Value
Asset-Based Valuation sums the fair market value of everything a company owns minus its liabilities. On paper, it is the most conservative of the 5 methods of valuation. In practice, it is the most dangerous for tech founders — because most asset-based approaches count only what is on the balance sheet.
Intangible assets now represent 92% of S&P 500 market capitalisation, up from 17% in 1975. Patents, proprietary datasets, trade secrets, algorithms, and trained models almost never appear at fair market value on a startup’s books. Some do not appear at all. An asset-based valuation that misses these intangibles is not conservative — it is wrong.
The fix is a proper IP-inclusive asset valuation. This requires identifying every protectable asset — granted and pending patents, trade secrets, proprietary data, documented know-how — and assigning each one a fair market value. Companies with patents are 10.2x more likely to secure early-stage funding, which means investors are already pricing these assets. Your valuation should too.
Method 4: Precedent Transactions — The M&A Gold Standard
Precedent Transactions values a company based on what acquirers actually paid for similar businesses. It uses real deal data — purchase prices, control premiums, and implied multiples from completed transactions. For M&A scenarios, this is the most credible method because it reflects what informed buyers actually wrote cheques for.
The IP premium in precedent transactions is measurable. Companies acquired with strong patent portfolios and documented trade secrets consistently command 30–60% higher prices than companies with comparable revenue but weaker IP positions. Hayat Amin showed this in a restructuring where founders expected a $2M portfolio valuation — the licensable-units approach revalued it at $14M, and the final deal closed at $11M.
Limitation: precedent transactions require comparable deals to exist and be public. In nascent sectors — edge AI, foundation model infrastructure, synthetic biology — deal data is scarce. When it exists, however, precedent transactions are nearly impossible for the other side to argue against.
Method 5: Relief from Royalty — The Valuation Method Most Founders Have Never Heard Of
Relief from Royalty calculates what a company would have to pay in royalties if it did not own its IP and had to license it from a third party. That hypothetical royalty cost, capitalised over the asset’s useful life, becomes the value of the IP. It is the only one of the 5 methods of valuation specifically designed to capture intangible asset value.
This is the method Hayat Amin’s Royalty Stack Framework builds on. The framework prices each IP asset against the licensee’s gross margin — software patents at 8–12% royalty, hardware at 3–6%, pharma at 5–20%. Stack the individual royalty streams, discount to present value, and you have a defensible number that speaks the language investors and acquirers understand.
For IP-heavy companies, Relief from Royalty consistently produces the highest — and most defensible — valuations. Beyond Elevation has used this approach to reveal value that other methods completely miss. In one engagement, DCF valued a portfolio at $1.8M. Relief from Royalty valued the same portfolio at $9.2M. The difference was the entire licensing revenue stream that DCF ignored because the first licence had not yet been signed.
The method works because it asks the right question: not “what does the IP earn today?” but “what would it cost to replace?” That reframing consistently unlocks 3–5x the value of income-only approaches.
Which Valuation Method Should You Use?
No single method gives you the full picture. The right approach depends on your company profile, and the strongest position uses multiple methods that triangulate to a defensible range. Hayat Amin reminds founders that the goal is not to pick the method that gives the highest number — it is to pick the methods that an investor, acquirer, or board member cannot dismiss.
AI companies: Comps + Relief from Royalty. Use comps to anchor in the market and Relief from Royalty to capture the IP premium. See the full framework in the 2026 AI multiples cheat sheet.
IP-heavy (patents, data, know-how): Relief from Royalty + Precedent Transactions. The royalty method captures asset-level value; precedent transactions validate it with real deal data.
Pre-revenue startups: Asset-Based (IP-inclusive) + Comps. DCF produces near-zero numbers for pre-revenue companies. Asset-based valuation with proper IP inclusion and sector comps gives you a credible floor and ceiling.
M&A exit positioning: All five. Serious acquirers will run their own versions of every method. Showing up with a triangulated valuation that addresses all five approaches makes your number harder to argue down. This is exactly what a Beyond Elevation valuation engagement produces.
FAQ
What is the most accurate valuation method for startups?
No single method is most accurate for startups. A combination of Comparable Company Analysis and IP-inclusive Asset-Based Valuation typically produces the most defensible range. DCF alone undervalues pre-revenue companies because it discounts speculative cash flows to near-zero.
How does IP affect company valuation?
IP directly increases valuation through the Relief from Royalty method and by commanding higher multiples in Comparable Company Analysis. Companies with patents are 10.2x more likely to secure early-stage funding and exit at 30–60% higher multiples. A properly valued patent portfolio adds measurable premium to any method.
What is the Relief from Royalty method?
Relief from Royalty calculates what a company would pay in royalties if it had to license its own IP from a third party. That capitalised royalty stream becomes the IP’s value. Hayat Amin’s Royalty Stack Framework uses industry-specific royalty rates — software 8–12%, hardware 3–6%, pharma 5–20% — to build a defensible number investors trust.
Which valuation method do VCs prefer?
VCs overwhelmingly use Comparable Company Analysis because it is fast and benchmarks against recent deals. However, the best investors also assess IP defensibility as a premium layer. Founders who present a triangulated valuation — comps for market context, Relief from Royalty for IP value — consistently negotiate stronger terms.
Can you use multiple valuation methods at once?
You should. Professional valuators always use at least two methods and triangulate. Using multiple methods reveals whether your number is anchored in market reality (comps), asset fundamentals (asset-based and relief from royalty), or future earnings (DCF). A single-method valuation is easy to dismiss; a triangulated one is not.